Sleep disturbance in adults with chronic pruritic dermatoses is associated with increased C-reactive protein levels - 11/01/21
Abstract |
Background |
Pruritus is a common symptom that can significantly reduce quality of life through sleep disruption.
Objective |
To examine features of disturbed sleep in patients with chronic pruritic dermatoses and test the hypothesis that systemic inflammation may serve as a biomarker for impaired sleep in these patients.
Methods |
Cross-sectional analysis of the National Health and Nutrition Examination Survey investigating systemic inflammation using C-reactive protein (CRP) levels. Logistic regression was used to compare patients with and without sleep disturbances, adjusting for demographics (model 1) and medical comorbidities (model 2).
Results |
Chronic pruritic dermatoses were associated with multiple sleep disturbances, including nighttime awakenings (model 1: odds ratio [OR], 1.646; 95% confidence interval [CI], 1.031-2.627; model 2: OR, 1.329; 95% CI, 0.888-1.989) and early morning awakening (model 1: OR, 1.669, 95% CI, 1.118-2.493; model 2: OR, 1.582; 95% CI, 1.008-2.481). Mean CRP levels were 52.8% higher among patients with pruritic dermatoses reporting trouble sleeping compared with those who did not (0.663 vs 0.434 mg/dL; P = .034). Trouble sleeping was also positively correlated with CRP levels (β = 0.142, P = .025).
Limitations |
Potential recall bias among participants.
Conclusions |
In addition to confirming sleep disturbances with pruritic dermatoses, we found these disturbances are more likely to present with elevated CRP levels. Clinicians should consider the potential risk for sleep-related and cardiac comorbidities in patients diagnosed with itchy skin conditions.
Le texte complet de cet article est disponible en PDF.Key words : biomarkers, C-reactive protein, dermatoses, eczema, inflammation, inflammatory, itch, NHANES, pruritic dermatoses, pruritic, pruritus, sleep
Abbreviations used : CI, CRP, NHANES, OR
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Shawn G. Kwatra is on the advisory board for Pfizer Inc, Regeneron Pharmaceuticals, and Menlo Therapeutics, has received grant funding from Pfizer Inc and Kiniksa Pharmaceuticals, and also received a Dermatology Foundation Medical Dermatology Career Development Award. Authors Patel, Khanna, Choi, Williams, Roh, Hong, Sutaria, Pritchard, and Madan M. Kwatra have no conflicts of interest. |
|
| IRB approval status: IRB approval was waived, because only an anonymous aggregate-level data count was used, and patient consent was not required. |
|
| Reprints not available from the authors. |
Vol 84 - N° 2
P. 265-272 - février 2021 Retour au numéro
Article précédent
- Progress toward diminishing the murkiness of Merkel cell carcinoma management
- Warren R. Heymann
- Association of interleukin-6 and tumor necrosis factor-? with mortality in hospitalized patients with cancer
- Joseph R. Stoll, Toral S. Vaidya, Shoko Mori, Stephen W. Dusza, Mario E. Lacouture, Alina Markova
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?